NCT00704951撤回不适用
P05532 Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections (IFIs) in Immuncompromised Patients in Austria. Version 1, 08-Nov-2007.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Safety: adverse events
研究概览
简要总结
The purpose of this program is to determine the frequency of the use of Posaconazole in immunocompromised patients refractory to first line therapy receiving therapeutic treatment based on different pathogens in comparison to other antifungal therapy.
A further objective is to determine the frequency of the use of Posaconazole in immunocompromised patients receiving prophylactic treatment in comparison to other antifungal prophylaxis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Immunocompromised patients with refractory IFI
- •Patients eligible for prophylactic treatment due to anticipated neutropenia for more than 7 days.
排除标准
- 未提供
研究组 & 干预措施
Patients
Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections
干预措施: Posaconazole or alternative fungal treatment (Drug)
结局指标
主要结局
Safety: adverse events
时间窗: Depending on treatment modality every 2 to 4 weeks
次要结局
- Baseline: Patient demographic data; Disease history; Underlying diseases; Diagnosis; Previous therapies; Environmental risk factors; Host factors Performance status(Depending on treatment modality every 2 to 4 weeks)
- Treatment and follow up period: Performance status; Medication; Duration of treatment; Frequency of infectious episodes; Management of infections(Depending on treatment modality every 2 to 4 weeks)
- Adverse events; Survival status(Depending on treatment modality every 2 to 4 weeks)
研究者
相似试验
进行中（未招募）
1 期
Study of posaconazole prophylaxis in patients receiving hematopoietic stem cell allograft (allo-HSC) at high risk of invasive fungal infection (IFI): POSALLO study30 adult patients due to receive an allograft for a myeloid or lymphoid hematological malignancy with an HLA-matched donor from the family or from the international donor file will be included in the hematology departments of the Nantes University Hospital.CTIS2024-511507-42-00Centre Hospitalier Universitaire De Nantes30
已完成
3 期
Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)MycosesNCT00034632Merck Sharp & Dohme LLC
已完成
3 期
Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)MycosesNCT00034658Merck Sharp & Dohme LLC336
已完成
4 期
A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface AreaHematological MalignancyNCT02372357Universitaire Ziekenhuizen KU Leuven14
已完成
2 期
A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)MycosesNCT00550732Merck Sharp & Dohme LLC40